Heart Failure and All-cause Hospitalizations can be Reduced During Ambulatory Monitoring Even in Patients Who cannot be Matched to Trial-type Patients.

Hemodynamic monitoring has been shown to reduce admissions for heart failure in both the large randomized CHAMPION Trial (CHMP) and a 1200 patient Post Approval Study registry (PAS). A persistent observation in heart failure (HF) studies is that trial patient populations differ from patients who are treated in clinical practice. After identifying patients who could be propensity matched to the CHMP trial patients, we studied the characteristics and outcomes of the patients who could not be matched. PAS was an FDA mandated registry to determine if results of the CHMP trial could be replicated in clinical practice, as reported previously. Propensity matching was done between CHMP Control and PAS patients. 387 PAS patients could be propensity matched and can be considered "Trial-Type" patients (TT) and 813 were not match able (NM). For each patient group heart failure (HFH) and all-cause (ACH) hospitalization rates at 1 year were compared to the rate in the year prior to enrollment. Compared to CHMP Treatment patients, NM patients were older 61.3 vs 71.8, more likely to be female (18.1% vs 39.6%) and have heart failure with normal ejection fraction (HFpEF) (23% vs 55.9%), p < 0.001 for all. Wedge pressure was higher (17.5 vs 20.0 mmHg) and GFR was lower (60.4 vs 50.5 mL/min/1.73 m²), p < 0.001 for both. Although ACH and HFH were higher in NM patients before and during PA pressure guided management, there was a significant decline in both after implantation of the CardioMEMS™ monitor (Figure 1). Of the 1200 patients in the PAS, 67% (813/1200) patients were not match able to typical trial subjects. Nonetheless, these patients with older age, worse renal function, and more hospitalizations still had significant reduction in rates of HFH and ACH during ambulatory hemodynamic monitoring. [ABSTRACT FROM AUTHOR]